Home/Verdiva Bio/Ashley Taylor

AT

Ashley Taylor

Chief Technology Officer

Therapeutic Areas

Obesity Cardiometabolic Disorders

Verdiva Bio Pipeline

Drug	Indication	Phase
VRB-101 (Oral)	Obesity	Phase 2
VRB-103 (Oral)	Obesity	Preclinical
VRB-101 + VRB-103 (Oral)	Obesity	Preclinical
VRB-101 + VRB-102 (Injectable)	Obesity	Preclinical
VRB-104	Undisclosed	Preclinical

Leadership Team at Verdiva Bio

Chief Executive Officer

Mohamed Eid, MD

Chief Medical Officer

Mark Pruzanski, MD

View full Verdiva Bio profile